Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01722708
Other study ID # 0012-12-EMC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2012
Est. completion date August 1, 2022

Study information

Verified date August 2022
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Abnormal vaginal flora is a risk factor for preterm labor. Therefore, in high risk pregnancies for preterm labor the diagnosis and treatment of abnormal flora is indicated. Clindamycin and metronidazole given orally are both acceptable treatments in these cases. The purpose of this study is to compare the effectiveness of Clindamycin Vs metronidazole for the treatment of abnormal vaginal flora in high risk pregnancies. For this purpose, pregnant women who are considered high risk for preterm labor and were diagnosed with abnormal vaginal flora will be randomly treated either with clindamycin or metronidazole. Eradication of the abnormal flora and adverse effects will be monitored and compared


Recruitment information / eligibility

Status Completed
Enrollment 169
Est. completion date August 1, 2022
Est. primary completion date August 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Pregnant women at increased risk for preterm labor (preterm cervical effacement, preterm uterine contractions, twins pregnancy, vaginal bleeding, past preterm delivery) - Age above 18 years Exclusion Criteria: - Known allergy to the tested antibiotics - Antibacterial treatment in the week before the vaginal culture was taken - preterm premature rupture of membranes

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clindamycin
Oral clindamycin 300 Milligrams*2/Day for a week
Metronidazole
Oral metronidazole 500 Milligrams*2/Day for a week

Locations

Country Name City State
Israel Departement of obstetric and gynecology, HaEmek medical center Afula
Israel Departement of obstetric and gynecology, Poriya Medical Center Tiberias

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora Primary outcome will be assessed by taking a vaginal culture sample a week after one-week antibacterial treatment
Secondary The prevalence of adverse effects During the antibacterial treatment which is 1 week of therapy
Secondary The prevalence of late abortions and preterm deliveries From date of randomization until the date of delivery or abortion, assessed up to 28 weeks
Secondary Assessing the correlation between Nugent score , physical examination and Ph indicators The outcome is assessed after the diagnosis of abnormal vaginal flora is made at 14-26 weeks of gestation
See also
  Status Clinical Trial Phase
Completed NCT01287728 - The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy Phase 3